Frontlight ResearchEarly access
Glioblastoma trials in Germany
19 of 27 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in GermanySIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Where
- Bonn, Lünen
- Age
- 18 years and over
- People
- 365 worldwide
- Run by
- Nuvation Bio Inc.
See details and how to joinNCT05303519 - Phase 1Not yet taking people in GermanySynergism of dendritic cell vaccination and anti-PD-L1 immune check-point blockade to sensitize recurrent glioblastoma to anti-tumoral immunity
- Where
- Duesseldorf, Duisburg
- Age
- 18 years and over
- People
- 6
- Run by
- Heinrich-Heine-Universitaet Duesseldorf
See details and how to join2026-525397-19-00 - Phase 2/3Active, not recruitingA Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- Where
- Bonn, Cologne, Frankfurt Am Main, Heidelberg, Mannheim, Regensburg, Tuebingen
- Age
- 18 years and over
- People
- 2,250 worldwide
- Run by
- Global Coalition for Adaptive Research
See details and how to joinNCT03970447 · EU 2024-511452-40-00 - Phase 2Not yet taking people in GermanyIDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
- Where
- Berlin, Bonn, Cologne, Dresden, Erlangen, Essen, Frankfurt, Heidelberg, Mannheim, Regensburg, Tübingen, Ulm, Würzburg
- Age
- 18 years to 70 years
- People
- 216
- Run by
- German Cancer Research Center
See details and how to joinNCT07888647 · EU 2026-526308-64-00 - No phaseNot yet taking people in GermanyAn Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM
- Where
- Tübingen
- Age
- 18 years and over
- People
- 30 worldwide
- Run by
- Boston Scientific Corporation
See details and how to joinNCT07867886 - Phase 2Taking peoplePhase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy (MecMeth/ NOA-24)
- Where
- Bochum, Bonn, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Freiburg im Breisgau, Heidelberg, Leipzig, München, Münster, Regensburg, Rostock, Tübingen
- Age
- 18 years and over
- People
- 72
- Run by
- Rheinische Friedrich-Wilhelms-Universitaet Bonn
See details and how to join2024-511264-89-00 - Phase 2Not yet taking people in GermanyStudy of Olutasidenib and Temozolomide in HGG
- Where
- Heidelberg
- Age
- 12 years to 39 years
- People
- 60 worldwide
- Run by
- Rigel Pharmaceuticals
See details and how to joinNCT06161974 - Early phase 1Not yet taking people in GermanyLorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Where
- Heidelberg
- Age
- 1 year to 21 years
- People
- 15 worldwide
- Run by
- Nationwide Children's Hospital
See details and how to joinNCT06333899 - Phase 1/2Taking peopleRadiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
- Where
- Muenster
- Age
- 18 years to 75 years
- People
- 34
- Run by
- Universität Münster
See details and how to joinNCT05590689 · EU 2024-517651-12-00 - Phase 1Not yet taking people in GermanyAn open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).
- Where
- Aachen, Cologne, Hamburg
- Age
- 18 years to 64 years
- People
- 27 worldwide
- Run by
- Double Bond Pharmaceutical AB
See details and how to joinNCT04967690 · EU 2024-515128-35-00 - Phase 3Taking peopleLomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
- Where
- Bochum, Cologne, Essen, Heidelberg, Jena, Munich, Tuebingen
- Age
- 18 years and over
- People
- 411 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT05904119 · EU 2023-505267-36-00 - No phaseTaking peopleLow-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial
- Where
- Bonn, Leipzig, Lünen, Mannheim, München, Stuttgart
- Age
- 18 years and over
- People
- 30
- Run by
- BioTex, Inc.
See details and how to joinNCT06533163 - Phase 2Not yet taking people in GermanyStudy of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Where
- Heidelberg
- Age
- 12 months to 39 years
- People
- 120 worldwide
- Run by
- Nationwide Children's Hospital
See details and how to joinNCT05843253 - No phaseTaking peopleGlioblastoma Radiotherapy Using IMRT or Proton Beams
- Where
- Heidelberg, Marburg, Stuttgart
- Age
- 18 years and over
- People
- 326
- Run by
- University Hospital Heidelberg
See details and how to joinNCT04752280 - Phase 1Taking peopleIntracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
- Where
- Frankfurt Am Main, Heidelberg, Mainz, Mannheim
- Age
- 18 years and over
- People
- 42
- Run by
- Johann Wolfgang Goethe University Hospital
See details and how to joinNCT03383978 · EU 2024-511988-29-01 - Phase 2Taking peopleSurgery for Recurrent Glioblastoma
- Where
- Erfurt, Münster
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Insel Gruppe AG, University Hospital Bern
See details and how to joinNCT02394626 - Phase 3Taking peopleAnterior Temporal Lobectomy in Temporal Glioblastoma
- Where
- Bonn
- Age
- 18 years to 74 years
- People
- 178
- Run by
- University Hospital, Bonn
See details and how to joinNCT07021339 - No phaseTaking peopleAmplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)
- Where
- Berlin
- Age
- 18 years to 70 years
- People
- 26
- Run by
- Charite University, Berlin, Germany
See details and how to joinNCT06140875 - Phase 1/2Not yet taking people in GermanySafety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
- Where
- Leipzig
- Age
- 18 years and over
- People
- 226 worldwide
- Run by
- Philogen S.p.A.
See details and how to joinNCT04443010 · EU 2024-516357-46-00